GenVec cuts 30% of jobs over revenue uncertainties
This article was originally published in Scrip
GenVec's stock price bounced up and down $0.10 in both directions on 25 September when the Gaithersburg, Maryland-based company announced that it will eliminate 23 jobs, or 30% of its work force, but the stock ultimately remained steady, closing at $1.69 per share from $1.68 the day before.
You may also be interested in...
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.